吉利德科学公司在第二季度的收益估计超过了预期, 提高了2025年的预期, Gilead Sciences beat earnings estimates in Q2, raised 2025 outlook, and stock near 1-year high.

Gilead Science公司报告说,第二季度收入为每股2.01美元,超过估计数0.05美元,收入为70.8亿美元,比上一年增加1.4%。 Gilead Sciences reported second-quarter earnings of $2.01 per share, exceeding estimates by $0.05, with revenue of $7.08 billion, up 1.4% year-over-year. 该公司将其2025年全年EPS指南提高到7.95至8.25美元,并保持了“Moderate Buy”的共识评级,目标价格为122.61美元。 The company raised its 2025 full-year EPS guidance to $7.95–$8.25 and maintains a "Moderate Buy" consensus rating with a target price of $122.61. 尽管有些内部出售,包括首席执行官丹尼尔·奥代(Daniel O ' Day)和主管约翰娜·梅西耶(Johanna Mercier),但机构所有权仍然高达83.67%。 Despite some insider selling, including CEO Daniel O’Day and executive Johanna Mercier, institutional ownership remains high at 83.67%. 股票交易额接近其1年最高值124.61美元,市场上限为1 494.8亿美元,P/E比率为24.00,PEG比率为0.83,反映了坚实的财政健康和稳定。 The stock, trading near its 1-year high of $124.61, has a market cap of $149.48 billion, a P/E ratio of 24.00, and a PEG ratio of 0.83, reflecting solid financial health and stability.